Navigation Links
Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
Date:7/17/2008

GlycoMark(R) Blood Test Now Established to Provide Physicians with Vital

Information Missed by Hemoglobin A1c Test to More Effectively Manage

Patients with Diabetes

NEW YORK and WINSTON-SALEM, N.C., July 17 /PRNewswire/ -- Toyota Tsusho America, Inc. (New York, NY) and Nippon Kayaku Co., Ltd. (Tokyo, Japan) announced today the formation of a new joint venture company, GlycoMark, Inc., dedicated to the discovery and commercialization of novel biomarkers for diabetes. The company is located in New York, NY and the Piedmont Triad Research Park in Winston-Salem, NC.

Toyota Tsusho America, Inc., Nippon Kayaku Co., Ltd., and the BioMarker Group (Kannapolis, NC) have worked together as partners to commercialize the GlycoMark(R) diabetes blood test over the past few years prior to establishing the new company. With increasing clinical acceptance and commercial success of the GlycoMark(R) blood test, a solid foundation has now been built to position GlycoMark, Inc. as a leader in the field of diabetes diagnostics.

"The GlycoMark(R) blood test is being increasingly utilized in clinical practice to manage patients with diabetes and in clinical drug studies," said John Buse, MD, PhD, director of the diabetes care center at the University of North Carolina School of Medicine, Chapel Hill. "The test is particularly useful in monitoring moderately controlled patients, where GlycoMark may be more dynamic than the gold standard hemoglobin A1C test in reflecting glucose levels, according to some recent studies."

"I am excited about the vision for this new company," said Eric Button, president and co-owner of GlycoMark, Inc. "We have already achieved several key clinical and commercialization milestones for GlycoMark(R) and the success of the test has put us in a strong position to transform testing for diabetes, a near-epidemic in the U.S. and worldwide."

GlycoMark(R) milestones include:

-- FDA approval

-- Establishment in diabetes care through numerous research publications in leading medical journals

-- Featured as a premier diagnostic test by Quest Diagnostics and LabCorp. Available at these and other prominent national medical reference laboratories.

-- Highlighted as an American Diabetes Association sponsored symposium at its 2008 annual meeting.

-- Recent study by Eli Lilly of over 2000 patients from eleven countries indicates that GlycoMark(R) reflects glycemia better than the current gold standard, Hemoglobin A1c, in moderately controlled diabetic patients.

-- GlycoMark(R) is best marker for efficacy for blockbuster drugs Byetta (Amylin/Lilly) and Januvia (Merck) in moderately controlled patients.

-- Inclusion in the International Diabetes Federation (IDF) Global Diabetes Care Guidelines.

-- Establishment of a scientific advisory board comprised of leading diabetologists worldwide.

The new company will focus initially on the continued commercialization of the GlycoMark(R) laboratory test with partner reference laboratories in the U.S. Preparations are currently underway for introduction of GlycoMark(R) internationally, including the European Union. The new joint venture company is also developing a point-of-care and home-test version of the GlycoMark(R) test.

About GlycoMark Blood Test

GlycoMark(R) is an FDA-approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control -- providing a useful complement to A1C testing. GlycoMark(R) is being used in clinical practices nationwide and is available at major reference laboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories, ARUP Laboratories, and Specialty Laboratories. The test is also available at most major contract research organizations for pharmaceutical research studies.

About Toyota Tsusho America, Inc.

Toyota Tsusho America, Inc. has emerged in the US market as a multi-business entity with expanded capabilities, fresh ideas, and a greatly broadened experience base. Toyota Tsusho America, Inc.'s seven operating divisions (Chemicals, Metals, Machinery & Electronics, Logistics, Automotive, Food, and Consumer Products) pursue a broad range of activities which combine international trading functions with domestic source and supply activities, supply chain and logistics services, and processing and manufacturing functions in both the industrial and consumer sectors.

About Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd. is a comprehensive fine chemical manufacturer, which had been established in Japan in 1916 and has continued to expand into a broad range of new fields including explosives, dyes, pharmaceuticals, in-vitro diagnostics, agrochemicals, functional products, catalysts, and automobile safety parts. Our products are distributed worldwide now. Nippon Kayaku Co., Ltd. pursues to serve customers in global niche markets with innovative products through a fusion of technology and human resources.


'/>"/>
SOURCE GlycoMark, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
2. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
3. Coalition America, Inc. Again Named One of Georgias Fastest Growing Technology Companies in Deloittes Technology Fast 50 Program
4. Ambulatory Services of America, Inc. Announces Joint Venture with Southern Ocean County Radiation Oncology, LLC
5. Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc.
6. Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP
7. Ambulatory Services of America, Inc. Announces Investment by Lindsay Goldberg
8. Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas
9. Ambulatory Services of America, Inc. Announces Joint Venture to Operate Chicago-Area Radiation Oncology Facility
10. Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri
11. National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... “Congratulations! It's ... value of children to both their parents and God. “Congratulations! It's A Boy! God’s ... Rachael Anthony, a couple from Long Island, New York. , Published by Christian Faith ...
(Date:8/18/2017)... ... ... ... For Immediate Release                Contact: Julian Teixeira, August ... Seek Sex and Relationship Advice from their Fathers , ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles ... focuses on resources available for individuals with hearing impairments and shares the latest ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Dawn ... is inaugurating a new charity drive to generate community support for efforts to educate ... into cures and treatments for all types of cancer. , Each day in ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , August 17, 2017 DarioHealth Corp. ... with mobile health and big data solutions, announced ... with domestic and non-U.S. investors for the sale ... shares of the Company,s newly designated Series B ... The Company expects to conduct a closing with ...
(Date:8/15/2017)... Pharmaceuticals Inc., the creator of the drug Truveta for the ... an IPO. The United States spends ... a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... figure is the fact that Americans spent $42 billion on anxiety medications ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. ... mobile health and big data solutions, today announced that ... Monday, August 14 and host a conference call at ... 2017 operating and financial results and its strategy and ... be hosted by Erez Raphael , Chief Executive ...
Breaking Medicine Technology: